mash novo nordisk - Search News

Order byBest matchMost fresh

News

Novo Nordisk, liver

Fierce Pharma · 2d

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Continue reading

· 4d · on MSN

Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH

Investor's Business Daily on MSN · 1d

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Pharmaceutical Technology5h

Madrigal wins European MASH approval as Novo rivalry looms

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Zacks.com on MSN1d

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results